Directive 2005/61 - Implementation of Directive 2002/98/EC as regards traceability requirements and notification of serious adverse reactions and events - Main contents
Please note
This page contains a limited version of this dossier in the EU Monitor.
Contents
official title
Commission Directive 2005/61/EC of 30 September 2005 implementing Directive 2002/98/EC of the European Parliament and of the Council as regards traceability requirements and notification of serious adverse reactions and events| Legal instrument | Directive |
|---|---|
| Number legal act | Directive 2005/61 |
| CELEX number i | 32005L0061 |
| Document | 30-09-2005 |
|---|---|
| Publication in Official Journal | 01-10-2005; OJ L 287M , 18.10.2006,OJ L 256, 1.10.2005,Special edition in Croatian: Chapter 15 Volume 015,Special edition in Bulgarian: Chapter 15 Volume 015,Special edition in Romanian: Chapter 15 Volume 015 |
| Effect | 21-10-2005; Entry into force Date pub. + 20 See Art 11 |
| End of validity | 31-12-9999 |
| Transposition | 31-08-2006; At the latest See Art 10.1 |
1.10.2005 |
EN |
Official Journal of the European Union |
L 256/32 |
COMMISSION DIRECTIVE 2005/61/EC
of 30 September 2005
implementing Directive 2002/98/EC of the European Parliament and of the Council as regards traceability requirements and notification of serious adverse reactions and events
(Text with EEA relevance)
THE COMMISSION OF THE EUROPEAN COMMUNITIES,
Having regard to the Treaty establishing the European Community,
Having regard to Directive 2002/98/EC of the European Parliament and of the Council of 27 January 2003 setting standards of quality and safety for the collection, testing, processing, storage and distribution of human blood and blood components and amending Directive 2001/83/EC (1), and in particular points (a) and (i) of the second paragraph of Article 29 thereof,
Whereas:
(1) |
Directive 2002/98/EC lays down standards of quality and safety for the collection and testing of human blood and blood components, whatever their intended purpose, and for their processing, storage and distribution when intended for transfusion so as to ensure a high level of human health protection. |
(2) |
In order to prevent the transmission of diseases by blood and blood components and to ensure an equivalent level of quality and safety, Directive 2002/98/EC calls for the establishment of specific technical requirements dealing with traceability, a Community procedure for notifying serious adverse reactions and events and the notification format. |
(3) |
Notification of suspected serious adverse reactions or serious adverse events should be submitted to the competent authority as soon as known. This Directive therefore establishes the notification format defining the minimum data needed, without prejudice to the faculty of Member States to maintain or introduce in their territory more stringent protective measures which comply with the provisions of the Treaty as provided under Article 4(2) of Directive 2002/98/EC. |
(4) |
This Directive lays down those technical requirements, which take account of Council Recommendation 98/463/EC of 29 June 1998 on the suitability of blood and plasma donors and the screening of donated blood in the European Community (2), Directive 2001/83/EC of the European Parliament and of the Council of 6 November 2001 on the Community code relating to medicinal products for human use (3), Commission Directive 2004/33/EC of 22 March 2004 implementing Directive 2002/98/EC of the European Parliament and of the Council as regards certain technical requirements for blood and blood components (4), and certain recommendations of the Council of Europe. |
(5) |
Accordingly, blood and blood components imported from third countries, including those used as starting material or raw material for the manufacture of medicinal products derived from human blood and human plasma, intended for distribution in the Community, should meet equivalent Community standards and specifications relating to traceability and serious adverse reaction and serious adverse event notification requirements as set out in this Directive. |
(6) |
It is necessary to determine common definitions for technical terminology in order to ensure the consistent implementation of Directive 2002/98/EC. |
(7) |
The measures provided for in this Directive are in accordance with the opinion of the Committee set up by Directive 2002/98/EC, |
HAS ADOPTED THIS DIRECTIVE:
Article 1
Definitions
For the purposes of this Directive, the following definitions shall apply:
(a) |
‘traceability’ means the ability to trace each individual unit of blood or blood component derived thereof from the donor to its final destination, whether this is a recipient, a manufacturer of medicinal products or disposal, and vice versa; |
(b) |
‘reporting... |
More
This text has been adopted from EUR-Lex.
This dossier is compiled each night drawing from aforementioned sources through automated processes. We have invested a great deal in optimising the programming underlying these processes. However, we cannot guarantee the sources we draw our information from nor the resulting dossier are without fault.
This page is also available in a full version containing the legal context, de Europese rechtsgrond, other dossiers related to the dossier at hand, the related cases of the European Court of Justice and finally consultations relevant to the dossier at hand.
The full version is available for registered users of the EU Monitor by ANP and PDC Informatie Architectuur.
The EU Monitor enables its users to keep track of the European process of lawmaking, focusing on the relevant dossiers. It automatically signals developments in your chosen topics of interest. Apologies to unregistered users, we can no longer add new users.This service will discontinue in the near future.